OBJECTIVE: Severe myelosuppression is a common side effect of radiotherapy or chemotherapy. Methods have been developed to protect patients by stimulating white blood cell or red blood cell recovery/production using growth factors such as G-CSF or EPO. However, there is no available means to stimulate the full-lineage blood cell recovery from severe myelosuppression. In this study, we used lethally or sublethally irradiated animal models to evaluate the hematopoiesis stimulating effect of IL-12. MATERIALS AND METHODS: IL-12-treated lethally or sublethally irradiated animals were examined for the survival/lifespan, the function assays (bone marrow transplantation, CFU-S(12), CFC) of bone marrow cell subsets, and apoptosis assay. RESULTS: Using a low dose of IL-12 (10 times lower than previously reported dose), 91.4% of lethally irradiated animals survived long term without adverse effects on the gastrointestinal (GI) system. The reconstituted hematopoietic system was derived from long-term reconstituting hematopoietic stem cells (LTR HSC), which reconstituted hematopoiesis both endogenously after lethal radiation and in secondary recipients by bone marrow transplantation (BMT). IL-12 significantly attenuated the decline of blood cell counts in sublethally irradiated animals. The IL-12-stimulated hematopoiesis recovery resulted in a full-lineage blood cell production, including white and red blood cells, and platelets. There was no detectable expression of IL-12 receptor on LTR HSC. In IL-12-treated animals, the number of Sca-1(+) cells was significantly higher than in animals without IL-12 treatment. CONCLUSION: In this study, we showed a low dose of IL-12 has hematopoietic-protecting effects, which can attenuate severe myelosuppresion caused by lethal or sublethal irradiation. This study, together with previous studies showing IL-12 is also an anti-tumor and anti-angiogenic agent, suggest IL-12 may have clinical significance in cancer treatment and BMT.
OBJECTIVE: Severe myelosuppression is a common side effect of radiotherapy or chemotherapy. Methods have been developed to protect patients by stimulating white blood cell or red blood cell recovery/production using growth factors such as G-CSF or EPO. However, there is no available means to stimulate the full-lineage blood cell recovery from severe myelosuppression. In this study, we used lethally or sublethally irradiated animal models to evaluate the hematopoiesis stimulating effect of IL-12. MATERIALS AND METHODS: IL-12-treated lethally or sublethally irradiated animals were examined for the survival/lifespan, the function assays (bone marrow transplantation, CFU-S(12), CFC) of bone marrow cell subsets, and apoptosis assay. RESULTS: Using a low dose of IL-12 (10 times lower than previously reported dose), 91.4% of lethally irradiated animals survived long term without adverse effects on the gastrointestinal (GI) system. The reconstituted hematopoietic system was derived from long-term reconstituting hematopoietic stem cells (LTR HSC), which reconstituted hematopoiesis both endogenously after lethal radiation and in secondary recipients by bone marrow transplantation (BMT). IL-12 significantly attenuated the decline of blood cell counts in sublethally irradiated animals. The IL-12-stimulated hematopoiesis recovery resulted in a full-lineage blood cell production, including white and red blood cells, and platelets. There was no detectable expression of IL-12 receptor on LTR HSC. In IL-12-treated animals, the number of Sca-1(+) cells was significantly higher than in animals without IL-12 treatment. CONCLUSION: In this study, we showed a low dose of IL-12 has hematopoietic-protecting effects, which can attenuate severe myelosuppresion caused by lethal or sublethal irradiation. This study, together with previous studies showing IL-12 is also an anti-tumor and anti-angiogenic agent, suggest IL-12 may have clinical significance in cancer treatment and BMT.
Authors: Scott A Gerber; Ryan J Cummings; Jennifer L Judge; Margaret L Barlow; Julee Nanduri; Doug E Milano Johnson; James Palis; Alice P Pentland; Edith M Lord; Julie L Ryan Journal: Radiat Res Date: 2015-01-07 Impact factor: 2.841
Authors: Jung Heon Kim; Donna Collins-McMillen; Jason C Buehler; Felicia D Goodrum; Andrew D Yurochko Journal: J Virol Date: 2017-02-14 Impact factor: 5.103
Authors: Juliann G Kiang; Min Zhai; David L Bolduc; Joan T Smith; Marsha N Anderson; Connie Ho; Bin Lin; Suping Jiang Journal: Radiat Res Date: 2017-08-29 Impact factor: 2.841
Authors: Qiang Fu; Maaike Berbée; Marjan Boerma; Junru Wang; Herbert A Schmid; Martin Hauer-Jensen Journal: Radiat Res Date: 2009-06 Impact factor: 2.841
Authors: Lena A Basile; Dolph Ellefson; Zoya Gluzman-Poltorak; Katiana Junes-Gill; Vernon Mar; Sarita Mendonca; Joseph D Miller; Jamie Tom; Alice Trinh; Timothy K Gallaher Journal: PLoS One Date: 2012-02-24 Impact factor: 3.240
Authors: Annie Bourdeau; Sébastien Trop; Karen M Doody; Daniel J Dumont; Michel L Tremblay; Michel L Tremblayef Journal: Stem Cells Date: 2013-02 Impact factor: 6.277